NFKB1 and cancer: For example, in lung stem-like cancer cells that display positivity of CD166, together with CD44 and EpCAM, the cells were found to be more sensitive to NFκB inhibitors for suppressing the expression of CD166, suggesting a strategy to target this small population of cancer cells for treatment [26,27].